



EUSA Pharma Company Overview

Date of Preparation: September 2021. GL-NPS-2100066
©2021 EUSA Pharma (UK) Ltd. All rights reserved.



EUSA Pharma

We Change Lives, Patient by Patient



EUSA Pharma

OUR EXECUTIVE COMMITTEE



Carsten Thiel
Chief Executive Officer



Emma Johnson
Chief Financial Officer



Jeroen Commissaris
Vice President, Emerging
Markets



Jon Morgan
Vice President, Global
Head of Regulatory and
Pharmacovigilance



Gary Whale
Vice President, Global
Head of Technical
Operations



Davide Paganoni
Vice President, Europe



Rabecka Martin
Vice President, Global and
US Medical Affairs




Claire Harding
Vice President, Global
Head of Human Resources



Dev Kumar
General Counsel and
Global Head of Compliance

ESTABLISHED DIRECT COMMERCIAL AND MEDICAL INFRASTRUCTURE



● EUSA Office

■ Direct Market – with commercial and medical presence

Global HQ

- EUSA Executive Committee and Leadership Team
- Core Global Functions
- Medical, Regulatory, Legal, Marketing, HR, Pricing, Supply Chain, Quality, Pharmacovigilance/Safety

Europe

- Local Commercial, Medical and Office Management

US


- Medical, Marketing and Sales
- Legal, HR, Finance
- Medical, Commercial and Office Management

Emerging Markets (LATAM, SE Asia, Australasia)

- Local Medical and Commercial Teams
- Centrally Driven and Supported



EUSA Pharma




Commercialisation
& Development
Agreement signed Jan
2020.
SYLVANT® Greater
China QARZIBA®
Mainland only

Not all Partnerships shown. Partnerships may represent distribution or licensing agreements. Partnerships may encompass single or multiple EUSA Pharma products. EAP Supply is only offered for individual named patients in full compliance with applicable laws regarding provision of unlicensed medicines in the relevant jurisdictions.

GLOBAL PRODUCT ACCESS THROUGH DIRECT OPERATIONS AND SELECT PARTNERSHIPS

■ Direct Market ■ Commercial Partnership ■ Managed Access Programme or Other Distribution



DIVERSE COMMERCIAL PRODUCT PORTFOLIO IN ONCOLOGY AND RARE DISEASE



Target: Ganglioside-D2 (GD2)

- Monoclonal antibody.
- Treatment of high-risk neuroblastoma patients aged 12 months and above, as first/front-line maintenance therapy, as well as patients with a history of relapsed or refractory disease
- Approved: EU, UK, Israel, Australia, Hong Kong, Brazil, China
- Commercial reimbursement across core European markets
- Supplied Globally (managed access programme) in 2020
- Under review: Russia, Mexico, Taiwan



Target: Interleukin-6 (IL-6)

- Monoclonal antibody.
- Treatment of multicentric Castleman disease (MCD) adult patients who are HIV and HHV-8 negative
- Approved: US, EU, UK, 40+ countries (Canada, Korea, Australasia, SE Asia, LATAM)
- Commercial reimbursement across core European markets and US
- Supplied commercially to over 40 countries in 2020
- Filed for approval in China with fast-track designation



Target: VEGF Receptors -1, -2 & -3

- Small molecule TKI.
- Treatment of 1L advanced renal cell carcinoma (aRCC) in adult patients who are VEGFR and mTOR pathway inhibitor-naïve
- Approved: EU, UK, New Zealand, South Africa
- Commercial reimbursement across core European markets
- Under review: Brazil, Argentina



Target: Oromucosal Inflammation

- Calcium Phosphate mouth rinse (supersaturated solution)
- Treatment and prevention of oral mucositis (chemo- & radiotherapy)
- Approved: US, EU, UK, China and multiple global markets
- Class I Medical Device in Europe
- Synergistic promotional fit with adult solid tumour commercial teams



To learn more about EUSA Pharma, please visit eusapharma.com